220
Participants
Start Date
May 28, 2025
Primary Completion Date
December 7, 2028
Study Completion Date
December 7, 2028
Ubamatamab
Administered per the protocol
Bevacizumab
Administered per the protocol
Cemiplimab
Administered per the protocol
Fianlimab
Administered per the protocol
PLD
Administered per the protocol
Sarilumab
Prophylaxis administered per the protocol
RECRUITING
Tri-Service General Hospital, Taipei
RECRUITING
Taipei Municipal Wan Fang Hospital, Taipei
RECRUITING
Changhua Christian Hospital, Changhua
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Korea University Guro Hospital, Seoul
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
National Cancer Center, Gyeonggi-do
RECRUITING
Mackay Memorial Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
Seoul National University Bundang Hospital, Seongnam-si
RECRUITING
Gachon University Gil Medical Center, Incheon
RECRUITING
Mayo Clinic Jacksonville, Jacksonville
RECRUITING
Tampa General Hospital Cancer Institute, Tampa
RECRUITING
The University of Alabama at Birmingham, Birmingham
RECRUITING
Norton Cancer Institute, St. Matthews Clinic, Louisville
RECRUITING
Keimyung University Dongsan Hospital, Daegu
RECRUITING
The Ohio State University Comprehensive Cancer Center, Hilliard
RECRUITING
Avera Cancer Institute Sioux Falls, Sioux Falls
RECRUITING
The University of Kansas Cancer Center, Westwood
RECRUITING
Swedish Cancer Institute, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Severance Hospital Yonsei University Health System, Seoul
RECRUITING
Asan Medical Center, Univ. of Ulsan, Seoul
RECRUITING
Samsung Medical Center, Seoul
Regeneron Pharmaceuticals
INDUSTRY